Effects of Paroxetine and Olanzapine Respectively Combined with Flupentixol-Melitracen on HAMD, BI and NIHSS Scores in Patients with Post-Stroke Depression
MA Han, WANG Hui, WANG Meng
Suzhou Hospital of Anhui Medical University / Suzhou Municipal Hospital, Anhui Suzhou 234000, China
Abstract：Objective: To investigate the effect of paroxetine and olanzapine respectively combined with flupentixol-melitracen on the quality of life of post-stroke depression patients. Methods: From February 2017 to April 2019, 126 patients with stroke depression in our hospital were randomly divided into 3 groups by random number table method, 42 cases each in paroxetine combination group, olanzapine combination group and control group. Paroxetine combination group received paroxetine combined with flupentixol-melitracen, olanzapine combination group received olanzapine combined with flupentixol-melitracen, and the control group received flupentixol-melitracen alone treatment. The course of treatment is 8 weeks. The treatment efficacy, NIHSS, HAMD, BI score, and adverse reactions of the three groups were compared. Results: The therapeutic effect of the paroxetine combination group and olanzapine combination group was better than that of the control group (Z=3.063, 2.301, P<0.05); The total effective rates of the paroxetine combination group and olanzapine combination group were 95.24% and 90.48%, significantly higher than 73.81% of the control group (P<0.0167). After treatment, the NIHSS and HAMD scores of the three groups were significantly decreased (P<0.05), and the BI score was significantly increased (P<0.05); NIHSS and HAMD of the paroxetine combineation group and olanzapine combination group were significantly lower than that of the control group (P<0.05), the BI score was significantly higher than the control group (P<0.05). The incidences of total adverse reactions in the paroxetine combination group, olanzapine combination group and control group after treatment were 66.67%, 80.95% and 78.57% respectively. There was no statistically significant difference in the incidence of total adverse reactions among the three groups (P>0.05 ). Conclusion: Paroxetine combined with flupentixol-melitracen and olanzapine combined with flupentixol-melitracen in stroke patients with depression has a significant therapeutic effect compared with the use of flupentixol-melitracen alone. It can effectively reduce the degree of neurological deficit and depression, improve the ability of life, and will not increase adverse reactions.
马汉, 王辉, 王梦. 帕罗西汀奥氮平分别联合氟哌噻吨美利曲辛治疗对脑卒中抑郁患者HAMD BI及NIHSS评分的影响[J]. 河北医学, 2021, 27(1): 156-159.
MA Han, WANG Hui, WANG Meng. Effects of Paroxetine and Olanzapine Respectively Combined with Flupentixol-Melitracen on HAMD, BI and NIHSS Scores in Patients with Post-Stroke Depression. HeBei Med, 2021, 27(1): 156-159.
[1] 曾强,解晔,王劲松.江苏省扬州市2018年心脑血管疾病全人群流行现状研究[J].实用临床医药杂志,2019,23(24):37~40. [2] Yousefpour A, Modarress H, Goharpey F, et al. Interaction of drugs amlodipine and paroxetine with the metabolizing enzyme CYP2B4: a molecular dynamics simulation study[J]. Journal of Molecular Modeling, 2018, 24(3):67. [3] Kulhan T, Husarova V M, Ondrejka I, et al. Anxiolytic effects of venlafaxine/olanzapine combination in treatment of anxious depression[J]. Neuro endocrinology letters, 2018, 38(8):579~585. [4] 潘晓峰,刘文娟.普拉克索联合行为疗法对早发帕金森病合并抑郁患者HAMDUPDRS评分非运动症状及生活质量的影响[J].河北医学,2019,25(8):1240~1243. [5] Kwon C Y, Lee B, Chung S Y, et al. Herbal medicine sihogayonggolmoryeo-tang or chai-hu-jia-long-gu-mu-li-tang for the treatment of post-stroke depression: a protocol for a systematic review and meta-analysis[J]. Medicine, 2018, 97(38):e12384. [6] 宋新虹,贺守彬.盐酸帕罗西汀治疗抑郁症的效果和不良反应[J].中国医药指南,2018,16(24):147~148. [7] Burak Y, Lutfu H, Ertugrul K. Commentary: toward a personalized medicine in wake-up stroke[J]. Cns & Neurological Disorders Drug Targets, 2018, 16(10):1049. [8] 冯福海,宋芳,谭诗云.氟哌噻吨美利曲辛结合法莫替丁治疗伴睡眠障碍胃食管反流病患者的临床观察及对血清5-HT、NE的影响[J].临床和实验医学杂志,2019,18(23):2530~2534.
2021, Vol. 27 
冀公网安备13080202000677号